8-K: Dexcom Reports Mixed Third Quarter Results Amidst Strategic Shifts

Dexcom's third quarter results show revenue growth of 2% year-over-year, but a decrease in operating income, alongside the launch of a new over-the-counter glucose biosensor and a leadership transition.

Summary

• Dexcom's revenue grew by 2% year-over-year to $994.2 million in the third quarter of 2024, or 3% on an organic basis.
• U.S. revenue declined by 2%, while international revenue increased by 12% on a reported basis and 16% organically.
• GAAP operating income decreased to $152.0 million, or 15.3% of revenue, a 580 basis point drop compared to the same quarter last year.
• Non-GAAP operating income was $212.0 million, or 21.3% of revenue, a 320 basis point decrease year-over-year.
• The company launched Stelo, its first over-the-counter glucose biosensor, and expanded its international product portfolio with Dexcom G7 in Australia and Dexcom ONE+ in France.
• Dexcom executed a $750 million share repurchase program.
• The company submitted the Dexcom G7 15-day CGM system to the FDA for review after the quarter ended.
• Dexcom is reiterating its 2024 annual guidance, including revenue of approximately $4.00 4.05 billion, 11-13% organic growth, a non-GAAP gross profit margin of approximately 63%, a non-GAAP operating margin of approximately 20%, and an adjusted EBITDA margin of approximately 29%.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative due to mixed results. While revenue grew, profitability metrics declined, and there are leadership changes. The launch of Stelo and international expansion are positive, but the overall financial performance is weaker than the previous year.

Positives

• Dexcom achieved 2% year-over-year revenue growth, reaching $994.2 million.
• International revenue grew by 12% on a reported basis and 16% organically, indicating strong global expansion.
• The launch of Stelo marks a significant step into the over-the-counter market.
• The company executed a $750 million share repurchase program, demonstrating confidence in its financial position.
• Dexcom is reiterating its full-year 2024 guidance, showing stability in its financial outlook.

Negatives

• U.S. revenue declined by 2% year-over-year, indicating potential challenges in the domestic market.
• GAAP operating income decreased by 580 basis points compared to the third quarter of 2023.
• Non-GAAP operating income also decreased by 320 basis points year-over-year.
• GAAP gross profit decreased to 59.7% of revenue, down from 63.9% in the same quarter last year.
• Non-GAAP gross profit decreased to 63.0% of revenue, down from 64.7% in the same quarter last year.

Risks

• The decline in U.S. revenue could indicate increased competition or market saturation.
• Decreased operating income and gross profit margins may impact profitability.
• The transition in commercial leadership could create uncertainty in sales and marketing strategies.
• The company faces risks related to intellectual property litigation.
• The company's forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially.

Future Outlook

Dexcom is reiterating its fiscal year 2024 guidance for revenue of approximately $4.00 4.05 billion, non-GAAP gross profit margin of approximately 63%, non-GAAP operating margin of approximately 20%, and adjusted EBITDA margin of approximately 29%.

Management Comments

• Dexcom's third quarter results were in line with our expectations as our team responded quickly to the business dynamics that emerged earlier this year, said Kevin Sayer, Dexcom's chairman, president and CEO.
• We made significant progress over the quarter to drive improved execution, leaving the company on track to continue on our momentum in the fourth quarter and into 2025, said Kevin Sayer.
• I want to personally thank Teri for her strong leadership and dedication, as seen most clearly through the successful launches of G7 and Stelo, said Kevin Sayer.

Industry Context

The launch of Stelo as an over-the-counter glucose biosensor positions Dexcom to capture a broader market, including individuals with prediabetes and type 2 diabetes not on insulin therapy. The international expansion with Dexcom G7 and ONE+ aligns with the trend of increasing global adoption of CGM technology.

Comparison to Industry Standards

• Dexcom's 2% revenue growth is lower than the 27% growth reported in the same quarter last year, indicating a slowdown in growth rate.
• The decrease in operating income and gross profit margins suggests potential challenges in cost management or pricing pressures.
• Compared to competitors like Abbott, which also operates in the CGM market, Dexcom's performance in the U.S. market appears weaker this quarter.
• The launch of Stelo is a significant move, as it directly competes with other over-the-counter glucose monitoring solutions, potentially expanding Dexcom's market reach beyond traditional CGM users.
• The $750 million share repurchase program is a common strategy among mature tech companies, but it may indicate a lack of other high-return investment opportunities.

Management Changes

Legal Proceedings

• The company has excluded third-party attorneys fees, costs, and expenses incurred by Dexcom exclusively in connection with Dexcoms patent infringement litigation against Abbott Diabetes Care, Inc.

Stakeholder Impact

• Shareholders may be concerned about the decrease in operating income and gross profit margins.
• Employees may experience uncertainty due to the leadership transition in the commercial organization.
• Customers may benefit from the launch of new products like Stelo and the expansion of Dexcom G7 and ONE+.
• Suppliers may see continued demand for Dexcom products, but may also be impacted by any changes in production or supply chain strategies.
• Creditors may be monitoring the company's financial performance and cash position.

Next Steps

• Dexcom will continue to focus on driving improved execution in the fourth quarter and into 2025.
• The company will conduct a global search for a new chief commercial officer.
• Dexcom will continue to expand production capacity and explore new market opportunities.

Key Dates

Keywords

Dexcom, CGM, continuous glucose monitoring, Stelo, Dexcom G7, diabetes, biosensor, revenue, operating income, share repurchase, FDA, financial results